Patients With PAH Who Discontinue Other Medications Due to Liver Abnormalities Fare Well With Ambrisentan
PHILADELPHIA -- November 4, 2008 -- Ambrisentan is a potential treatment for patients with pulmonary arterial hypertension (PAH) who fail to respond to other endothelin receptor antagonists due to liver function test abnormalities, according to researchers speaking here at CHEST 2008, the annual meeting of the American College of Chest Physicians.